Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 24, 2022
Reporting Period: Event date May 24, 2022; Signed May 31, 2022.
Context: The Company is a biopharmaceutical entity listed on the NASDAQ Global Market under the symbol "MBIO". This filing addresses a regulatory notice regarding stock listing compliance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance issue.
Material Changes
- Stock Price Deficiency: The Company received notice from Nasdaq that its common stock bid price closed below $1.00 per share for 30 consecutive business days.
- Regulatory Status: The Company is currently non-compliant with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- Immediate Effect: The notice has no immediate effect on the listing of shares; trading continues.
Guidance, Outlook, and Risks
- Compliance Timeline: The Company has been granted a 180-calendar day grace period ending November 21, 2022, to regain compliance.
- Remediation Criteria: Compliance requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the grace period.
- Future Options: If compliance is not met by November 21, 2022, the Company may be eligible for an additional 180-day period if it meets initial listing criteria and intends to cure the deficiency via a reverse stock split.
- Delisting Risk: There is no assurance the Company will maintain its Nasdaq listing. Failure to comply could lead to delisting, though the Company may request a hearing before the Nasdaq Hearings Panel to stay delisting actions.
- Management Action: Management intends to monitor the stock price and consider all available options but has not yet made a decision on specific remedial actions.
Investor Verification Checklist
- Verify the current closing bid price of MBIO stock relative to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential implementation of a reverse stock split.
- Track the Company's progress toward achieving 10 consecutive days of compliance before the November 21, 2022 deadline.
- Review subsequent filings for any updates on the Nasdaq compliance status or hearing requests.